Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02852655
Title A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma

gliosarcoma

high grade glioma

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.